Papers of interest

• Antimicrobial resistance surveillance in Europe, 2020 data
  WHO & ECDC, January 2022
• Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
  The Lancet, January 19, 2022, online
• At 5 years, CARB-X celebrates progress on antibiotic development
  Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota
• 2020 Antibacterial agents in clinical and preclinical development: an overview and analysis
  World Health Organization, 2021
• Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States
  Dzintars Gotham et al, Health Policy, November 2020 (Open Access)
• Precarious antibiotics supply situation: Will the Covid19 Pandemic change anything? (translation D–>E)
  Beyer P,, Swiss medical Forum 47-48: 701-705 (November 2020) (Open Access)
• Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe
  A look at four potential financing models with an evaluation from a European perspective
  Årdal C, Lacotte Y, and Ploy MC (EU-JAMRAI), Clin. Infect. Dis. 71: 1994 (2020)
• No money for new drugs
  Despite an overwhelming global need for pharmaceutical companies to develop more antibiotics, there’s little financial incentive to encourage them
  Benjamin Plackett, Nature 586, 22 October 2020
• Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus
  Morel CM, Lindahl O. & al., J. Antibiotics 73: 421-428 (2020)
• Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study
  Strich J.R. & al., Lancet Inf. Dis.: June 4 (2020)
• Antibiotic development — economic, regulatory and societal challenges
  Årdal C., Balasegaram M. & al., Nature Rev. Microbiol. 18: 267 (2020)
• The global preclinical antibacterialpipeline
  Theuretzbacher U., Outterson K. & al., Nature Rev. Microbiol. 18: 275(2020)
• Priority pathogens and the antibiotic pipeline: an update
  Beyer P. & Paulin S., Bull. WHO 90: 151 (2020)
• Biological Risks in Switzerland: Antibiotic resistances
  The Swiss Expert Committee for Biosafety SECB produced has a document for biological risks related to Antibiotic Resistance (November 2019)
• The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later
  Description of the state of antimicrobial resistance worldwide 6 years after the first report
  A paper from Lancet Infectious Diseases, 11 February 2020
  Crisis Looms in Antibiotics as Drug Makers Go Bankrupt
  First Big Pharma fled the field, and now start-ups are going belly up, threatening to stifle the development of new drugs
  A paper from the New York Times (26.12.2019)
• CAESAR annual report 2018
  WHO Central Asian and Eastern European Surveillance of Antimicrobial Resistance report containing the Swiss data (from Anresis.ch), November 2019
• Swiss Antibiotic Resistance Report 2018
  Anresis.ch, ARCH-Vet; November 2019
• Incentivising a sustainable response to the threat of AMR
  BEAM Alliance, November 2019
• Chimeric peptidomimetic antibiotics against Gram-negative bacteria
  Luther A., Urfer M., et al., Nature, 23 October 2019

• Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis
  Benjamin N. R. & al., Clin. Infect. Dis., Open accepted manuscript (20 October 2019)